Catalina Lighting Inc (NASDAQ:CALA) Institutional Investor Sentiment Trend

Calithera Biosciences, Inc. (NASDAQ:CALA) Logo

Sentiment for Catalina Lighting Inc (NASDAQ:CALA)

Catalina Lighting Inc (NASDAQ:CALA) institutional sentiment increased to 0.91 in Q3 2018. Its up 0.24, from 0.67 in 2018Q2. The ratio improved, as 31 active investment managers increased or started new equity positions, while 34 sold and reduced their holdings in Catalina Lighting Inc. The active investment managers in our partner’s database now hold: 18.95 million shares, up from 18.33 million shares in 2018Q2. Also, the number of active investment managers holding Catalina Lighting Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 14 Reduced: 20 Increased: 23 New Position: 8.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $163.94 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

The stock decreased 0.23% or $0.01 during the last trading session, reaching $4.3. About 55,235 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has declined 49.90% since January 14, 2018 and is downtrending. It has underperformed by 49.90% the S&P500.

Analysts await Calithera Biosciences, Inc. (NASDAQ:CALA) to report earnings on March, 14. They expect $-0.48 earnings per share, down 54.84 % or $0.17 from last year’s $-0.31 per share. After $-0.52 actual earnings per share reported by Calithera Biosciences, Inc. for the previous quarter, Wall Street now forecasts -7.69 % EPS growth.

Bvf Inc Il holds 1.17% of its portfolio in Calithera Biosciences, Inc. for 2.54 million shares. Franklin Street Advisors Inc Nc owns 81,580 shares or 0.06% of their US portfolio. Moreover, Hikari Power Ltd has 0.05% invested in the company for 100,000 shares. The Pennsylvania-based Federated Investors Inc Pa has invested 0.02% in the stock. Quantitative Systematic Strategies Llc, a Connecticut-based fund reported 15,272 shares.

More notable recent Calithera Biosciences, Inc. (NASDAQ:CALA) news were published by: Benzinga.com which released: “Benzinga’s Biotech Pulse: vTv Swoons On Failed Alzheimer’s Trial, Regenxbio Gets FDA Fast Track For RGX-111 – Benzinga” on June 13, 2018, also Benzinga.com with their article: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines (June 3-9) – Benzinga” published on June 03, 2018, Fool.com published: “5 Best Biotech Stocks of 2017 So Far – The Motley Fool” on June 25, 2017. More interesting news about Calithera Biosciences, Inc. (NASDAQ:CALA) were released by: Finance.Yahoo.com and their article: “The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial – Yahoo! Finance News” published on December 21, 2018 as well as Globenewswire.com‘s news article titled: “Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma – GlobeNewswire” with publication date: April 18, 2018.

Calithera Biosciences, Inc. (NASDAQ:CALA) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.